Corbus Pharmaceuticals Holdings, Inc. - 8-K Filing

Corbus Pharmaceuticals reports statistically significant weight loss in Phase 1b CANYON-1 trial of CRB-913 for obesity treatment. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CRBP

Read the full article at SEC EDGAR

More Regulatory news